Navigation Links
YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
Date:10/11/2007

statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... "RegeneRx") today announced that it has received a ... Aging by Actin-Sequestering Peptides.  This patent includes claims ... and numerous other actin-sequestering peptides for these purposes.  ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
(Date:9/30/2014)... BioHealth Innovation, Inc. (BHI), a ... and increasing access to early-stage funding in ... Tania Fernandez , Ph.D., has joined the BHI ... a member of the management team for a new ... million in seed and early-stage equity investments to therapeutics, ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... DIEGO, March 20, 2012   CareFusion announced today ... Food and Drug Administration (FDA) for its new electrodiagnostic ... EDX system is a multi-modality device for monitoring and ... system. (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ...
... LAKE CITY, March 20, 2012 Remedy Informatics, the ... research, announced that Renton, Wash.-based Providence Health & ... registries for their Orthopedic Institute and Telestroke Network to ... http://photos.prnewswire.com/prnh/20120206/SF47874LOGO ) "We are excited to work ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 3
(Date:9/30/2014)... any aquatic environment on Earth, but when the climate ... to the limit. The amount of time needed to ... different species cope in the future, reveals a new ... in the scientific journal Proceedings of the Royal ... to increasing levels of greenhouse gases in the atmosphere. ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... 2012) - The many factors that contribute to how cells ... not fully understood, but researchers at Baylor College of ... intracellular membranes fuse, and in the process, created a new ... the current edition of the journal PLoS Biology . ...
... Cytori Therapeutics (NASDAQ: CYTX) announced today the publication ... Company,s European clinical trial evaluating adipose-derived stem and ... infarction (heart attack or AMI), as Research Correspondence ... of Cardiology . The APOLLO trial was a ...
... (NAS) has awarded John Waterbury, scientist emeritus in the ... the 2012 Gilbert Morgan Smith Medal. Waterbury is ... recognition of their extraordinary scientific achievements in a wide ... sciences. The recipients will be formally recognized in a ...
Cached Biology News:Membrane fusion a mystery no more 2Adipose stem cell heart attack trial data published in JACC 2WHOI's John Waterbury receives NAS Gilbert Morgan Smith Medal 2
... is a 96-well ELISA-compatible plate containing ... (mouse IgG 1 ) is directed ... (GST), and binds with high affinity ... in which the tag is exposed. ...
... Laboratory (RTL) can provide you with ... ,,Microbial method development and validation ,Performance ... conditions of your GMP manufacturing environment ... offer a full spectrum of microbiological ...
... years of experience in the development of ... to large and small peptides, proteins, haptens, ... DNA-encoded antigens. We understand and appreciate that ... development programs are never "cookbook". We will ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
Biology Products: